Safety and efficacy of atezolizumab/bevacizumab in unresectable hepatocellular carcinoma—a multicentric study

Abstract Purpose Immunotherapy with atezolizumab and bevacizumab is the current first-line standard of care for unresectable hepatocellular carcinoma (HCC). This study aimed to evaluate the safety and efficacy profile of atezolizumab-bevacizumab in the Indian population, as there are limited studies...

Description complète

Enregistré dans:
Détails bibliographiques
Auteurs principaux: Merin Babu, Ashok Sebastian Komaranchath, Arun Valsan, Arun R. Warrier, Rakesh MP, Wesley M. Jose, Nikhil K. Haridas, Sumi Soman, Manjima P. Nair, Shine Sadasivan, Abhinav Menon, Mohammed Thabrez, Keechilat Pavithran
Format: Artigo
Langue:Inglês
Publié: BMC 2025-07-01
Collection:BMC Cancer
Sujets:
atezolizumab
bevacizumab
hepatocellular carcinoma
real world
immune checkpoint inhibitors
Accès en ligne:https://doi.org/10.1186/s12885-025-14400-9
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires